Clinical Trial Update: Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial in newly diagnosed castration-sensitive prostate cancer evaluating combination therapy with enzalutamide and abiraterone plus standard…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castrate Sensitive Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING